BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1758 related articles for article (PubMed ID: 19340526)

  • 1. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
    Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T
    Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions.
    Ozcan Kara P; Kara T; Kara Gedik G; Kara F; Sahin O; Ceylan Gunay E; Sari O
    Nucl Med Commun; 2011 Feb; 32(2):106-12. PubMed ID: 21085046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adrenal nodules at FDG PET/CT in patients known to have or suspected of having lung cancer: a proposal for an efficient diagnostic algorithm.
    Brady MJ; Thomas J; Wong TZ; Franklin KM; Ho LM; Paulson EK
    Radiology; 2009 Feb; 250(2):523-30. PubMed ID: 19188319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adrenal masses in patients with cancer: PET/CT characterization with combined CT histogram and standardized uptake value PET analysis.
    Perri M; Erba P; Volterrani D; Guidoccio F; Lazzeri E; Caramella D; Mariani G
    AJR Am J Roentgenol; 2011 Jul; 197(1):209-16. PubMed ID: 21701032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic performance of unenhanced computed tomography and
    Delivanis DA; Bancos I; Atwell TD; Schmit GD; Eiken PW; Natt N; Erickson D; Maraka S; Young WF; Nathan MA
    Clin Endocrinol (Oxf); 2018 Jan; 88(1):30-36. PubMed ID: 28815667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidental non-secreting adrenal masses in cancer patients: intra-individual comparison of 18F-fluorodeoxyglucose positron emission tomography/computed tomography with computed tomography and shift magnetic resonance imaging.
    Gratz S; Kemke B; Kaiser W; Heinis J; Behr TM; Höffken H
    J Int Med Res; 2010; 38(2):633-44. PubMed ID: 20515577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDG-PET and CT characterization of adrenal lesions in cancer patients.
    Jana S; Zhang T; Milstein DM; Isasi CR; Blaufox MD
    Eur J Nucl Med Mol Imaging; 2006 Jan; 33(1):29-35. PubMed ID: 16193311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PET/CT for the characterization of adrenal masses in patients with cancer: qualitative versus quantitative accuracy in 150 consecutive patients.
    Boland GW; Blake MA; Holalkere NS; Hahn PF
    AJR Am J Roentgenol; 2009 Apr; 192(4):956-62. PubMed ID: 19304700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current generation time-of-flight (18)F-FDG PET/CT provides higher SUVs for normal adrenal glands, while maintaining an accurate characterization of benign and malignant glands.
    Koopman D; van Dalen JA; Stigt JA; Slump CH; Knollema S; Jager PL
    Ann Nucl Med; 2016 Feb; 30(2):145-52. PubMed ID: 26644009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18F-FDG PET/CT in the evaluation of adrenal masses.
    Metser U; Miller E; Lerman H; Lievshitz G; Avital S; Even-Sapir E
    J Nucl Med; 2006 Jan; 47(1):32-7. PubMed ID: 16391184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
    Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
    Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Total lesion glycolysis as the best 18F-FDG PET/CT parameter in differentiating intermediate-high risk adrenal incidentaloma.
    Kim YI; Cheon GJ; Paeng JC; Cho JY; Kang KW; Chung JK; Kim EE; Lee DS
    Nucl Med Commun; 2014 Jun; 35(6):606-12. PubMed ID: 24598843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic importance of 18F-FDG PET/CT parameters and total lesion glycolysis in differentiating between benign and malignant adrenal lesions.
    Ciftci E; Turgut B; Cakmakcilar A; Erturk SA
    Nucl Med Commun; 2017 Sep; 38(9):788-794. PubMed ID: 28692494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDG-PET/CT for diagnosis of primary ovarian cancer.
    Kitajima K; Suzuki K; Senda M; Kita M; Nakamoto Y; Onishi Y; Maeda T; Yoshikawa T; Ohno Y; Sugimura K
    Nucl Med Commun; 2011 Jul; 32(7):549-53. PubMed ID: 21407140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adrenal lesions: characterization with fused PET/CT image in patients with proved or suspected malignancy--initial experience.
    Blake MA; Slattery JM; Kalra MK; Halpern EF; Fischman AJ; Mueller PR; Boland GW
    Radiology; 2006 Mar; 238(3):970-7. PubMed ID: 16505394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What parameters from 18F-FDG PET/CT are useful in evaluation of adrenal lesions?
    Kunikowska J; Matyskiel R; Toutounchi S; Grabowska-Derlatka L; Koperski L; Królicki L
    Eur J Nucl Med Mol Imaging; 2014 Dec; 41(12):2273-80. PubMed ID: 25027709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinical efficacy of (18)F-FDG-PET/CT in benign and malignant musculoskeletal tumors.
    Shin DS; Shon OJ; Han DS; Choi JH; Chun KA; Cho IH
    Ann Nucl Med; 2008 Aug; 22(7):603-9. PubMed ID: 18756363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance of 18F-FDG PET/CT in the Characterization of Adrenal Masses in Noncancer Patients: A Prospective Study.
    Guerin C; Pattou F; Brunaud L; Lifante JC; Mirallié E; Haissaguerre M; Huglo D; Olivier P; Houzard C; Ansquer C; Hindié E; Loundou A; Archange C; Tabarin A; Sebag F; Baumstarck K; Taïeb D
    J Clin Endocrinol Metab; 2017 Jul; 102(7):2465-2472. PubMed ID: 28431167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Focal thyroid lesions incidentally identified by integrated 18F-FDG PET/CT: clinical significance and improved characterization.
    Choi JY; Lee KS; Kim HJ; Shim YM; Kwon OJ; Park K; Baek CH; Chung JH; Lee KH; Kim BT
    J Nucl Med; 2006 Apr; 47(4):609-15. PubMed ID: 16595494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of MR imaging and FDG-PET/CT in the differential diagnosis of benign and malignant vertebral compression fractures.
    Cho WI; Chang UK
    J Neurosurg Spine; 2011 Feb; 14(2):177-83. PubMed ID: 21214309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 88.